The short answer
Reported effects span actin sequestration, cell migration, angiogenesis, corneal wound healing and cardiac repair models. Actin sequestration is the best established and the most attributable to the fragment; the repair literature is more extensive and largely used full-length thymosin beta-4.
Key facts
- Best established
- G-actin sequestration
- Well supported
- Cell migration in vitro
- Reported
- Angiogenesis, corneal and cardiac repair
- Dominant evidence type
- In vitro and animal models
- Compound in repair work
- Largely full-length Tβ4
- Human clinical data
- Limited
Sorted by how well established
Actin sequestration is the firmest: it is the protein's recognised molecular function, mechanistically characterised, and the fragment carries the motif associated with it. Cell migration follows, with a short mechanistic route from actin and consistent in vitro results. Angiogenesis and tissue repair are more distant. These are real reported findings, but with longer causal chains and more dependence on the specific model.
The corneal work
Sosne and colleagues reported in Experimental Eye Research in 2002 that thymosin beta-4 promotes corneal wound healing and decreases inflammation in an animal model. The cornea is a useful system for wound work (accessible, avascular, and easy to image), and this is among the more frequently cited findings in the field. It used the protein.
Research material referenced
TB-500 5mg, third-party HPLC tested
The cardiac work
Shrivastava and colleagues reviewed thymosin beta-4 and cardiac repair in the Annals of the New York Academy of Sciences in 2010. Cardiac repair attracted substantial interest because the heart regenerates poorly, making any candidate promoting repair notable. Again, the protein.
The pattern worth noticing
The findings that make TB-500 interesting commercially (wound healing, tissue repair, cardiac regeneration) are largely findings about thymosin beta-4. The findings most attributable to TB-500 itself are the molecular ones. That inversion is the single most useful thing to hold in mind when reading marketing material about this compound.
What is absent
Substantial human clinical data. Registered interventional trials of the heptapeptide. Independent confirmation that the fragment reproduces the protein's repair effects. None of these absences refutes anything; together they mark where the evidence stops.
Frequently asked questions
What is TB-500 best established for?
Actin sequestration: the recognised molecular function of its parent protein, and the activity the fragment's motif carries.
Is the wound-healing evidence about TB-500?
Largely about full-length thymosin beta-4. The distinction is routinely lost in secondary writing.
Is there human clinical evidence?
Limited. The literature is predominantly in vitro and animal work.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedSosne G et al., Thymosin beta 4 promotes corneal wound healing. Exp Eye Res 2002 (PMID 11950239)pubmed.ncbi.nlm.nih.gov
- PubMedShrivastava S et al., Thymosin beta4 and cardiac repair. Ann N Y Acad Sci 2010 (PMID 20536454)pubmed.ncbi.nlm.nih.gov
- PubMedGoldstein AL et al. Expert Opin Biol Ther 2012 (PMID 22074294)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · Thymosin β4 (RGN-259) dry eye Phase 3 (NCT03925727)clinicaltrials.gov
- PubChemPubChem · Thymosin β4 (CID 16132341)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More TB-500 (Thymosin β4 fragment) articles
- TB-500 in the Published ResearchHow to search a literature where the compound name and the studied molecule frequently differ, and what the search strategy should be.
- Fragment Research: The Logic and Its LimitsIsolating a motif attributes an effect to that motif. What that buys, what it costs, and why fragment results do not automatically transfer to the parent.
- What Does TB-500 Stand For?TB is thymosin beta; 500 is a development series number carrying no chemical meaning. Why a code name became a product name, and what that obscures.
- TB-500: Names, Spellings and What Each FindsTB-500, TB500, Tβ4, thymosin beta-4, LKKTETQ. Which term finds the science, which finds the market, and why they return different things.
- BPC-157 and TB-500 Together: What the Evidence SaysThe two are frequently combined commercially, including in blends. Whether the research literature supports studying them together is a separate question.